STABILITY INDICATING ASSAY AND ESTIMATION OF IRBESARTAN BY FIRST ORDER UV DERIVATIVE SPECTROPHOTOMETRY
HTML Full TextSTABILITY INDICATING ASSAY AND ESTIMATION OF IRBESARTAN BY FIRST ORDER UV DERIVATIVE SPECTROPHOTOMETRY
Gunjan Kalyani*1 and Baikuntha Adjuad 2
Shri Rawatpura Sarkar, Institute of Pharmacy 1, Kumhari, Durg - 490042, Chhattisgarh, India.
Government V.Y.T. PG Autonomous College 2, Durg - 491001, Chhattisgarh, India.
ABSTRACT: Introduction: Irbesartan is chemically 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl) phenyl] phenyl} methyl) -1,3-diazaspiro [4.4] non-1-en-4-one. Irbesartan is an Angiotensin II receptor antagonist effective in the treatment of Hypertension. It is also effective in the treatment of High blood pressure. It is also effective when used alone or in combination with other drugs. Aims and Objectives: Objective of the present study is to develop a simple, sensitive, accurate, precise and rapid first order derivative spectrophotometric method for the estimation of irbesartan in pure form. Results: For the estimation of irbesartan, solvent system employed was 50% v/v aqueous ethanol and wavelength of detection (λdet) was 237 nm. The linearity was obtained in the range 8 -18 µg/ml, with a regression coefficient, R2 = 1. Discussion: Obtained results showed that there is minimum intraday and inter day variation. The developed method was validated and recovery studies were also carried out. Sample recovery using the above method was in good agreement with their respective labeled claims, thus suggesting the validity of the method and non-interference of formulation excipients in the estimation. First order derivative spectroscopy method is simple, rapid and reproducible and further it can be used for the analysis.
Keywords: |
Irbesartan, SIAM, First Order, Derivative spectroscopy, UV Spectrophotmeter
INTRODUCTION: Irbesartan is chemically 2-butyl - 3-({4- [2- (2H- 1, 2, 3, 4 - tetrazol- 5-yl) phenyl] phenyl}methyl) -1,3-diazaspiro [4.4] non-1-en-4-one. Irbesartan is an Angiotensin II receptor antagonist effective in the treatment of Hypertension1. It is also effective in the treatment of High blood pressure 1. It is also effective when used alone or in combination with other drugs. Irbesartan is a nonpeptide tetrazole derivative and an angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor.
In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II. Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium.
Angiotensin II also acts as a vasoconstrictor in vascularsmooth muscle 1. Irbesartan, by blocking the binding of angiotensin II to the AT1 receptor, promotes vasodilation and decreases the effects of aldosterone.
The negative feedback regulation of angiotensin II on renin secretion is also inhibited, but the resulting rise in plasma renin concentrations and consequent rise in angiotensin II plasma concentrations do not counteract the blood pressure–lowering effect that occurs. The action of ARBs is different from ACE inhibitors, which block the conversion of angiotensin I to angiotensin II, meaning that the production of angiotensin II is not completely inhibited, as the hormone can be formed via other enzymes. Also, unlike ACE inhibitors, irbesartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough) 1.
FIG. 1: STRUCTURE OF IRBESARTAN
UV spectrophotometry is generally preferred especially by small-scale industries as the cost of the equipment is less and the maintenance problems are minimal. The method of analysis is based on measuring the absorption of a monochromatic light by colorless compounds in the near ultraviolet path of spectrum (190-380nm). The fundamental principle of operation of spectrophotometer covering UV region consists in that light of definite interval of wavelength passes through a cell with solvent and falls on to the photoelectric cell that transforms the radiant energy into electrical energy.
Literature review suggested several analytical methods that have been reported for the estimation of Irbesartan in bulk or pharmaceutical formulations include High Performance Liquid Chromatography, and UV - Visible Spectro- photometry.
Literature review also revealed that there is no First order Derivative Spectroscopic method: The objective of the work was to develop simple, accurate, precise and economic first order derivative Spectroscopic method to estimate the candesartan in bulk. The method should be simple, accurate, precise, reproducible and statistically valid. Thus, the objectives of project:
- To develop a simple, precise, accurate method, less time consuming & economical derivative spectroscopic method.
- Under derivative spectroscopy, the development of First Order derivative Method.
- Validation of developed method using common parameters.
- Development of SIAM.
MATERIALS AND METHODS:
Drug: The standard sample of Ibresartan was obtained as gift sample from Dr. Reddy’s Laboratory Pvt. Ltd., Hyderabad, Andhra Pradesh, India. The Irbesartan tablets were procured from local market.
Instrument specifications: UV Spectrophotometer, Shimadzu, model 1800.
Chemicals and reagents used: Ethanol obtained from local market, manufactured by Merck Pharmaceuticals.
Preparation of stock solution: The stock solution of irbesartan is prepared by dissolving 100 mg of drug in 100 ml methanol in volumetric flask with continuous shaking; 0.08 ml of sample was withdrawn and diluted to 10 ml methanol to get 8 μg/ml of solution. The solution was than scanned in UV range between 200 - 400 nm UV-VIS Spectrophotometer, Shimadzu, Japan to determine the absorption maxima of the drug against blank as methanol.
Wavelength scanning and determination of absorption maximum: From the stock solution of Irbesartan, known concentration of 8μg/ml is prepared by suitable dilution with 50 % aqueous ethanol. Wavelength scanned for the maximum absorption of drug solution using UV-Visible spectrophotometer within the wavelength region of 200 - 400 nm against blank solvent.
FIG. 2: WAVELENGTH SCANNING AND DETERMINATION OF ABSORPTION MAXIMUM
Convert the normal mode obtained spectra to first order derivative. The wavelength that shows the peak with a highest absorbance is considered as absorbance maximum of the drug. The result is presented in Fig. 2.
Linearity studies: Stock solution was subsequently diluted with methanol to get 4μg/ml, 6μg/ml, 8μg/ml, 10μg/ml, 12μg/ml 14μg/ml, 16μg/ml, 18μg/ml 20μg/ml, 22μg/ml 24μg/ml. Convert the normal mode obtained spectra to first order derivative using software UV probe 2.34. The results are tabulated and the linearity curve was constructed by plotting concentration Vs. D1 value. The result is presented in Table 1 and Fig. 3.
TABLE 1: LINEARITY OF IRBESARTAN
S.no. | Concentration (µg/ml) | D1 value at detection wavelength (237 nm) |
1 | 8 | 0.012 |
2 | 10 | 0.015 |
3 | 12 | 0.018 |
4 | 14 | 0.021 |
5 | 16 | 0.024 |
6 | 18 | 0.027 |
FIG. 3: STANDARD GRAPH OF IRBESARTAN
Precision: The precision of method was ascertained; the percent relative standard deviation were calculated and presented.
Inter day and intraday studies for Irbesartan analytical method: The prepared stock solution was subsequently diluted to get 14μg/ml. The resulting solution absorbance was measured at detection wavelength of 237 nm using double beam UV spectrophotometer against blank solvent. The findings was made at different time intervals in day times in a day and performed continuously for six days. Convert the normal mode obtained spectra to second order derivative. The results obtained were tabulated and studied for inter day and intraday variation. The results are tabulated in Table 2 and Table 3.
TABLE 2: INTRADAY PRECISION
S. no. | Conc.
(µg/ml) |
D1 value at detection wavelength (237 nm) | ||||
Time (Mins) | I | II | III | Mean | ||
1 | 14 | 0 min. | 0.020 | 0.020 | 0.020 | 0.020 |
2 | 14 | 15 min | 0.020 | 0.020 | 0.021 | 0.02033 |
3 | 14 | 30 min | 0.020 | 0.020 | 0.021 | 0.02033 |
4 | 14 | 60 min | 0.020 | 0.021 | 0.020 | 0.02033 |
5 | 14 | 120 min | 0.021 | 0.020 | 0.020 | 0.02033 |
6 | 14 | 180 min | 0.021 | 0.021 | 0.021 | 0.021 |
7 | 14 | 240 min | 0.020 | 0.020 | 0.020 | 0.020 |
Mean = | 0.020 | |||||
SD = | 0.000333 | |||||
% RSD = | 1.66 |
TABLE 3: INTER DAY PRECISION
S. No. | Conc.
(µg/ml) |
Days | I | II | III | D1 at 237 nm(mean) |
1 | 14 | 1st | 0.021 | 0.021 | 0.020 | 0.021 |
2 | 14 | 2nd | 0.020 | 0.020 | 0.021 | 0.02033 |
3 | 14 | 3rd | 0.020 | 0.020 | 0.021 | 0.02033 |
4 | 14 | 4th | 0.021 | 0.021 | 0.020 | 0.022066 |
5 | 14 | 5th | 0.021 | 0.020 | 0.020 | 0.02033 |
6 | 14 | 6th | 0.021 | 0.021 | 0.021 | 0.021 |
Mean = | 0.020 | |||||
SD = | 0.000329 | |||||
% RSD = | 1.64 |
Accuracy Studies: The accuracy/recovery studies were carried out by adding a known amount of drug from the pre-analyzed tablet powder and percentage recoveries were calculated. Convert the normal mode obtained spectra to first order derivative. The reproducibility of estimation was determined by performing the tablet drug content of different samples. The results of accuracy studies were expressed in %. The result is presented in Table 4.
TABLE 4: ACCURACY STUDIES
S. no. | Test (µg/ml) | Standard (µg/ml) | D1 value at 237 nm | Conc. (µg/ml) | Amount of test recovered (µg/ml) | % Recovery |
1 | 3 | 6 | 0.0136 | 9.06 | 3.06 | 102.2% |
2 | 6 | 6 | 0.018 | 12.00 | 6.00 | 100.0% |
3 | 9 | 6 | 0.022 | 14.66 | 8.66 | 96.22% |
TABLE 5: DEPICTING THE ASSAY STUDIES
S. no. | Conc. (µg/ml) | D1 value at 237 nm | Conc. of drug in test solution(µg/ml) | % Purity (w/w) |
1 | 14 | 0.021 | 14 | 100 |
2 | 14 | 0.021 | 14 | 100 |
3 | 14 | 0.021 | 14 | 100 |
Assay studies: The assay studies were carried out with the help of Irbesartan tablets. The percentage purity was calculated. Convert the normal mode obtained spectra to first order derivative. The reproducibility of estimation was determined by performing the drug content of different samples. The results of assay studies were expressed in %. The result is presented in Table 5.
Stability studies:
Acid degradation: Accurately weighed 10 mg of the drug was taken in a 10 ml volumetric flask and few drops methanol were added to dissolve the drug. The volume was made up with freshly prepared 0.1N HCl. Then this solution was kept inside a water bath maintained at a temperature of 70°C. Samples were withdrawn in regular interval of 1 hour and the absorbance were measured at the determined λdet and recorded.
Alkali degradation: Accurately weighed 10 mg of the drug was taken in a 10 ml volumetric flask and minimum amount of methanol were added to dissolve the drug. The volume was made up freshly prepared 0.1N NaOH. This solution was kept inside a water bath maintained at a temperature of 70 °C. The samples were withdrawn in regular interval of 1 hour and the absorbance were measured at the determined λdet and recorded.
Oxidation degradation: Accurately weighed 10 mg of the drug was taken in a 10 ml volumetric flask and few drops of methanol were added to dissolve the drug and the volume was made up with freshly prepared 3% H2O2. The samples were withdrawn in regular interval of 6 hour for 36 hours and absorbance were measured at the determined λdet and recorded.
Neutral conditions: The stress medium selected was distilled water. Accurately weighed 10 mg of the drug was taken in a 10 ml volumetric flask and few drops of methanol were added to dissolve the drug and the volume (Table 1).
TABLE 6: STABILITY STUDY RESULTS OF IRBESARTAN
S. No. | Parameters | Obtained Results (Degradation) | Acceptance of results |
1 | Acidic stress (0.1 N HCl) | 45 % degradation | ü |
2 | Basic stress (0.1 N NaOH) | 46 % degradation | ü |
3 | Oxidative stress (6% H2O2) | 55 % degradation | ü |
4 | Thermal stress (Hot air oven; 80 oC) | 21% degradation | ü |
5 | Aqueous hydrolysis (distilled water) | 40 % degradation | ü |
6 | Photolytic stress (Sunlight) | 40% degradation | ü |
RESULTS AND DISCUSSION: Irbesartan is a novel, potent, highly selective non peptide Angiotensin II type 1 (AT1) receptor blocker which is administered orally. It is rapidly and completely hydrolyzed to the active moiety, during absorption from the gastrointestinal tract. The physico-chemical characteristic study of Irbesartan like melting point is 180°C nearer to the literature value 182°C in previous literature. The literature survey ascertains that HPLC analytical method is developed for Irbesartan, which is cost effective. In our laboratory we developed first order derivative spectroscopic method for the analysis of irbesartan. The known concentration of irbesartan is prepared and scanned for absorption maximum. The detection wavelength according to spectra is 237 nm. Different measured D1 values at detection wavelength 237.0 nm is plotted as the curve as D1 value versus concentration. Irbesartan obeys the beer’s law in the concentration range 8-18 μg/ml. Linearity study indicates the curve is linear in the range of 8 to 18 μg/ml. The linear regression equation is Y = 0.001x +0.012 with regression coefficient, R2 = 1.
The developed method is validated for repeatability, reproducible and the accuracy and precision. In the inter day and intraday study of standard graph, the % RSD is less than 2% indicating the developed method is reproducible. The different levels of standard concentration solutions are measured for D1 value and actual concentration is calculated. The results showed that the amount recovered is 100% indicating the first order derivative spectroscopic method is accurate and precise.
CONCLUSION: The developed analytical method for Irbesartan by using first order derivative spectroscopy is found to simple, rapid and selective and the amount of drug recovered will be same as the label claimed and precise. It can be conveniently employed for the routine analysis and quantification of Irbesartan. For forced degradation study the absorbance’s in all stressed condition was decreased for repeated times and percent degradation was found out. So, the drug undergoes degradation in all stressed condition. Based on the results obtained, it is found that the proposed methods are accurate, precise, reproducible and economical and can be employed for routine quality control of Irbesartan in its pharmaceutical dosage form.
ACKNOWLEDGEMENTS: Author (Gunjan Kalyani) would sincerely thank Guide Respected Vishal S. Deshmukh Sir for being a source of inspiration during this research work. And thanks to staff & lab technicians SRIP, Kumhari for providing basic facilities in lab.
CONFLICTS OF INTEREST: Nil.
REFERENCES:
- Erk N. Simultaneous determination of Irbesartan and hydrochlorthiazide in human plasma by liquid chromatography. J Chromatography.
- Budavari S., O’Neil M.J., Smith A. Heckelman P.E. Ed. The Merck Index, Mary Adele 13th edition published by Merck Research Lab, Division of Merck and Co., White house station, NJ, USA, 2001, 148.
- Shah N.J., Suhagia B.H., Shah R.R. and Shah P.B., 2007., Development and Validation of a HPTLC method for the simultaneous estimation of Telmisarta and Hydrochlorothiazide in tablet dosage form., Indian J Pharm Sci., 69: 202-5.
- Ganesan M.: “Method development and validation of Irbesartan using LCMS/MS: Application to pharmacokinetic studies”, Chem. Pharm. Res., 2010; 2 (4),740-746
- S: The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals, White House Station, N. J., Thirteenth edition. 2001.
- Williams, A.D: Foye’s Principles of Medicinal Chemistry, Fifth edition 2002.
How to cite this article:
Kalyani G and Adjuad B: Stability indicating assay and estimation of Irbesartan by first order UV derivative spectrophotometry. Int J Pharm Sci Res 2017; 8(9): 3817-21.doi: 10.13040/IJPSR.0975-8232.8(9).3817-21.
All © 2013 are reserved by International Journal of Pharmaceutical Sciences and Research. This Journal licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.
Article Information
23
3817-3821
426
1120
English
IJPSR
G. Kalyani*and B. Adjuad
Shri Rawatpura Sarkar, Institute of Pharmacy, Kumhari, Durg, Chhattisgarh, India.
kalyani.gunjan@yahoo.in
02 February, 2017
14 July, 2017
11 August, 2017
10.13040/IJPSR.0975-8232.8(9).3817-21
01 September, 2017